Relapsed CLL
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (NCT03639324) | Virginia Commonwealth University | 2020-10-02 |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (NCT03774654) | Baylor College of Medicine | 2020-04-14 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) (NCT03091933) | Ciusss de L'Est de l'Île de Montréal | 2017-02-06 |
Track Relapsed CLL automatically
Every clearance here is in the API, with alerts when new ones post.